Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914379 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3337641 in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02914379: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT02914379 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02914379, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how much LY3337641 gets into the bloodstream and how long it takes the body to get rid of it. In addition, the safety and tolerability of the study drug will be evaluated. Participants will be admitted to a clinical research unit (CRU) the day before dosing. Participants remain confined to the CRU for at least 7 days. Participants may be discharged from the CRU any time after 7 days post-dose (Day 8), and up to a maximum of 21 days post-dose (Day 22). This study will last approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.
Primary Outcome
Urinary excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in urine samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in urine and feces.
Interventions
- DRUG [¹⁴C]-LY3337641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-09 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
What the finished NCT02914379 record still lists
NCT02914379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]-LY3337641 is the first listed.
NCT02914379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02914379 about?
NCT02914379 is a clinical study titled "A Study of LY3337641 in Healthy Male Participants". The purpose of this study is to measure how much LY3337641 gets into the bloodstream and how long it takes the body to get rid of it. In addition, the safety and tolerability of the study drug will be evaluated. Participants will be admitted to a clinical research unit (CRU) the day before dosing. ...
What is the current status of trial NCT02914379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-09. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02914379?
The interventions under investigation include: [¹⁴C]-LY3337641 (DRUG).
Who is sponsoring clinical trial NCT02914379?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02914379's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia